Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 303

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 303
---
 is based on its consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of DiamiR’s consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, DiamiR evaluates our estimates based on historical experience, known trends and events and various other factors, which management believes to be reasonable under the circumstances, the results of which form the basis for judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The notes to our audited consolidated financial statements, which are included elsewhere in this proxy statement/prospectus, contain a summary of DiamiR’s significant accounting policies. DiamiR considers the following accounting policies and estimates critical to the understanding of the results of its operations. 176 Founder Contributions DiamiR was capitalized by its two founders with a cash contribution by one of its founders of $250,000 for 2,200,000shares of common stock and a non -cashcontribution by the other founder for 2,000,000shares of common stock. The founders subsequently made contributions to DiamiR in the form of uncompensated services and loans bearing interest at interest rates DiamiR believes to be below market value. DiamiR recorded discounts on founder notes payable of $35,063 and $101,221 in the years ended May 31, 2024 and 2023, respectively, and $24,970 in the nine months ended February 28, 2025 as additional paid -incapital. DiamiR also recorded expenses of $0 and $18,348 for the estimated value of uncompensated services in the years ended May 31, 2024 and 2023, respectively, and $0 in the nine months ended February 28, 2025 as additional paid -incapital. Grants Received from Government Agencies Research and development grants received from government institutions are recognized as revenue as related research obligations are performed, with qualified expenses classified as expenses. If grant funds are received in advance of performance, they are initially recognized as liabilities, to the extent they are refundable. Since inception, DiamiR has raised over $9.7 million grant funding from government agencies and disease foundations. On October 1, 2020, DiamiR announced that it received two